# 510(k) Summary-Precinorm CK-MB & Precipath CK-MB

# Introduction

Roche Diagnostics Corporation hereby submits this Special 510(k): Device Modification to provide notification of modifications to our Precinorm CKMB Control. This control was originally cleared for use in K003158, along with a CK-MB reagent and calibrator system on Roche/Hitachi Analyzers.

Modifications to the control include:

Change of name for Precinorm CK-MB to Precipath CK-MB (no change of analyte concentration), and New, additional control level with reduced levels of CK and CK-MB to normal levels. This new level is now called Precinorm CK-MB.

Submitter name, address, contact

Roche Diagnostics 9115 Hague Rd Indianapolis IN 46250 (317) 521-7637

Contact person: Kerwin Kaufman

Date prepared: September 28, 2006

# Device Name

Proprietary name: Precinorm CK-MB and Precipath CK-MB Controls

Common name: Single (Specified) Analyte Controls (assayed and unassayed)

Classification name: Quality control material (assayed and unassayed)

# Device Description

Precinorm CK-MB is for use in quality control by monitoring accuracy and precision for the quantitative methods as specified in the enclosed value sheet. Precipath CK-MB is for use in quality control by monitoring accuracy and precision for the quantitative methods as specified in the enclosed value sheet.

Precinorm CK-MB is a lyophilized controls based on bovine serum albumin. Adjusted activities of the control components are usually in the normal range or at the normal/pathological threshold. Precipath CK-MB is a lyophilized controls based on bovine serum albumin. Adjusted activities of the control components are usually in the pathological range. Biological additives for both control levels include CK-MM from human origin and CK-BB from porcine brain.

# 510(k) Summary-Precinorm CK-MB & Precipath CK-MB, Continued

# Intended use

Precinorm CK-MB is for use in quality control by monitoring accuracy and precision for the quantitative methods as specified in the enclosed value sheet.

Precipath CK-MB is for use in quality control by monitoring accuracy and precision for the quantitative methods as specified in the enclosed value sheet.

# Predicate Device

We claim substantial equivalence to the Precinorm CK-MB control cleared in K003158.

Substantial equivalency - Similarities/Diff erences   

<table><tr><td rowspan=1 colspan=1>Feature</td><td rowspan=1 colspan=1>Predicate device:Precinorm CK-MB(K003158)</td><td rowspan=1 colspan=1>Modified device:Precinorm CK-MB andPrecipath CK-MB</td></tr><tr><td rowspan=1 colspan=1>Intended Use(from labeling)</td><td rowspan=1 colspan=1>Precinorm CK-MB is for use in thequality control of Roche methods forthe quantitative determination ofCK-MB and creatine kinaseactivities. The control is used formonitoring accuracy and precisionboth for manual techniques and forassays on clinical chemistryanalyzers.</td><td rowspan=1 colspan=1>Precinorm CK-MB is for use inquality control by monitoringaccuracy and precision for thequantitative methods as specified inthe enclosed value sheet.Precipath CK-MB is for use inquality control by monitoringaccuracy and precision for thequantitative methods as specified inthe enclosed value sheet.</td></tr><tr><td rowspan=1 colspan=1>Reagentcomposition</td><td rowspan=1 colspan=1>Lyophilized control serum based onbovine serum albumin withchemical additives and material ofbiological origin.</td><td rowspan=1 colspan=1>Same</td></tr></table>

The table below indicates the similarities and differences between the modified Precinorm CK-MB control and its predicate device (Precinorm CKMB, K003158). Note that the predicate device is now sold as Precipath CKMB (no change in analyte concentration) as described above.

# 510(k) Summary-Precinorm CK-MB & Precipath CK-MB, Continued

Substantial equivalency - Similarities/Differences (continued)   

<table><tr><td rowspan=1 colspan=1>Feature</td><td rowspan=1 colspan=1>Predicate device:Precinorm CK-MB(K003158)</td><td rowspan=1 colspan=1>Modified device:Precinorm CK-MB andPrecipath CK-MB</td></tr><tr><td rowspan=1 colspan=1>ActiveIngredient Level</td><td rowspan=1 colspan=1>Precinorm CK-MB:CK and CK-MB usually atpathological level</td><td rowspan=1 colspan=1>Precinorm CK-MB:CK and CK-MB usually at normalrange or at the normal/pathologicalthreshold.Precipath CK-MB:CK and CK-MB usually atpathological level</td></tr><tr><td rowspan=1 colspan=1>Stability - shelflife and open vial</td><td rowspan=1 colspan=1>2-8 째C until expiration dateReconstituted:24 hours at 25째 C3 days at 4째 C1 month at -20째 C (freeze only once)</td><td rowspan=1 colspan=1>SameSame</td></tr><tr><td rowspan=1 colspan=1>Traceability</td><td rowspan=1 colspan=1>Traceability of the target values isgiven in the respective instructionsfor use of the system reagent to beused in combination with therecommended calibrator.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>ValueAssignment</td><td rowspan=1 colspan=1>The value assignment takes place inthree internal laboratories. Eachlaboratory runs at least threeindependent series. An independentseries includes full calibration usinga new calibrator vial and samplevial. The mean is used as setpoint.Controls which have to be assignedare used as samples. The mastercalibrator is used for calibration.</td><td rowspan=1 colspan=1>Same</td></tr></table>

# OCT 1 3 2006

Mr. Kerwin Kaufman Roche Diagnostics PO Box 50457 9115 Hague Rd Indianapolis, IN 46250

Re: k062972 Trade/Device Name: Precinorm CK-MB and Precipath CK-MB Controls Regulation Number: 21 CFR 862.1660 Regulation Name: Quality control material (assayed and unassayed) Regulatory Class: Class I, reserved Product Code: JJX Dated: September 28, 2006 Received: September 29, 2006

Dear Mr. Kaufman:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The alcnos provisi heccl eents  trai, st devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

Page 2 -

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240) 276-0484. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address   
http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

![](images/6a01ec5b08ab962627109a3ddfe4a200708106e65592d873669d3ccdcdb7d8f5.jpg)

Alberto Gutierez, Ph.D.   
Director   
Division of Chemistry and Toxicology   
Office of In Vitro Diagnostic Device Evaluation and Safety   
Center for Devices and Radiological Health

# Indications for Use

510(k) Number (if known):

# Device Name: Precinorm CK-MB and Precipath CK-MB Controls

Indications For Use:

Precinorm CK-MB is for use in quality control by monitoring accuracy and precision for the quantitative methods as specified in the enclosed value sheet.

Precipath CK-MB is for use in quality control by monitoring accuracy and precision for the quantitative methods as specified in the enclosed value sheet.

The Precinorm CK-MB and Precipath CK-MB are assayed quality control material intended for medical purposes for use in Roche test systems to estimate test precision and to detect systematic analytical deviations that may arise from reagent or analytical instrument variation.